Navigation Links
Onyx Pharmaceuticals Announces First Quarter 2008 Financial Results Teleconference and Webcast
Date:4/29/2008

EMERYVILLE, Calif., April 29 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will webcast a teleconference with management to discuss first quarter 2008 financial results and provide a general business overview on Tuesday, May 6, 2008, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Financial results for the first quarter ended March 31, 2008 will be released earlier that day.

Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/wt/page/event_calendar or by dialing 630-691-2760 and using the passcode 21488196. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 21488196 approximately one hour after the teleconference concludes. The replay will be available through June 6, 2008.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R), a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer, and other cancers. For more information about Onyx, visit the company's website at http://www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Core Informatics Delivers Enterprise Core LIMS Installation to BioRelix Pharmaceuticals
2. Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration
3. Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
4. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
5. Keryx Biopharmaceuticals Receives Nasdaq Notification
6. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition
9. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
10. New Fragment-based Drug Discovery Platform Announced Between IOTA Pharmaceuticals Ltd, Cambridge (UK), and Beactica AB, Uppsala (Sweden)
11. MacroChem Acquires Virium Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... NLP ... the years of diagnostic excellence by Mayo Clinic and the experience in developing ... will be distributed through the Microsoft Azure platform and will focus on assisting ...
(Date:7/26/2017)... , July 26, 2017  Nurse practitioners play a ... the findings of a Merck Manuals survey released ... medical conference, revealed that most (88 percent) believe they spend ... treatments and prescriptions. ... Merck Manuals survey of 210 nurse ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... and improve efficiency of livestock farming while reducing the use of antibiotics and ... intellectual property from Cornell University. , These new proprietary technologies expand the ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... US and Canada who have proven their superior service quality as rated by ... Staffing as an industry leader based on service quality ratings from their placed ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
Breaking Biology News(10 mins):